Germany’s Boehringer Ingelheim and South Korean firm Yuhan Corp (000100: KS) today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of non-alcoholic C (NASH) and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.
The collaboration brings together Yuhan’s expertise in FGF21 biology, obesity and NASH with family-owned Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.
News of the deal saw Yuhan’s shares close up 2.86% at 251,500 won today, having hit an intraday high of 267,500 won, despite the fact that research efforts on NASH candidates have seen a string of disappointments so far.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze